DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Council on Parkinson's Research, Care, and Services (ACPRCS).

This is the inaugural meeting of the ACPRCS, which was established by the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act of 2024 (Pub. L. 118–66). The Advisory Council is charged with providing advice to the HHS Secretary on Parkinson's-related issues, including the creation of a national plan. During the inaugural meeting of the Council, NIH/HHS will introduce and swear in a slate of Advisory Council members; federal agencies will provide an overview of Parkinson's programs; and the Advisory Council will strategize on their initial workplan.

The meeting will be open to the public to attend virtually via HHS Live Streaming: *www.hhs.gov/live.* Individuals wishing to participate in need of special assistance or other reasonable accommodations should submit a request to the Contact Person listed on this notice at least seven (7) business days prior to the meeting.

Name of Committee: Advisory Council on Parkinson's Research, Care, and Services (ACPRCS).

Date: June 29, 2026.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: To introduce the new Advisory Council members, provide an overview of Parkinson's programs by committee Federal Agencies, and strategize the initial workplan for the duties of the committee.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Cost: The meeting is free and open to the public.

Deadlines: Public Comment Due Date: June 22nd by 5:00 p.m. ET. For public comment instructions and guidelines, see below.

Contact Person: Jordan Gladman, Ph.D., Deputy Executive Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, *nationalPDplan@nih.gov*.

Public Comments: The ACPRCS welcomes written and oral/virtual public comments and asks the public to review and adhere to its Public Comment Guidelines provided at *https://www.ninds.nih.gov/current-research/trans-agency-activities/national-plan-end-parkinsons.*

Submissions are accepted in writing via email addressed to *NationalPDplan@nih.gov.* Please include the phrase ''public comment'' in the subject line as well as the body of the message. A limited number of slots are available for individuals to provide a ~3-minute oral summary or excerpt of their written comment to the Council during the meeting via videoconference. For those interested in that opportunity, please indicate ''Interested in providing oral/virtual comment'' in your written submission, along with your name, address, email, phone number, and professional/organizational affiliation so that Council support staff can contact you if a slot is available.

For any given meeting, priority for comment slots will be assigned to individuals and organizations that have not previously provided comments in the current calendar year. This will help ensure that as many individuals and organizations as possible have an opportunity to share comments. Commenters going over their allotted 3-minute slot may be asked to conclude immediately in order to allow other comments and the rest of the meeting to proceed on schedule.

Public comment submissions received by 5:00 p.m. ET on June 22nd will be provided to the Council prior to the meeting for their consideration. The Council is not able to respond individually to comments. All public comments become part of the public record. Attachments of copyrighted publications are not permitted, but web links or citations for any copyrighted works cited may be provided.

Technical issues: If you experience any technical problems with the webcast, please email *nationalPDplan@nih.gov.*

Disability Accommodations: All ACPRCS Full Council Meetings provide Closed Captioning through *www.hhs.gov/live.* Individuals whose full participation in the meeting will require special accommodations (*e.g.,* sign language or interpreting services) must submit a request to the Contact Person listed on the notice at least seven (7) business days prior to the meeting. Such requests should include a detailed description of the accommodation needed and a way for the ACPRCS to contact the requester if more information is needed to fill the request. Special requests should be made at least seven (7) business days prior to the meeting; last-minute requests may be made but may not be possible to accommodate.

Meeting schedule subject to change.

More Information: Information about the ACPRCS is available on: *https://www.ninds.nih.gov/current-research/trans-agency-activities/national-plan-end-parkinsons*.

Dated: May 18, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–10117 Filed 5–19–26; 8:45 am]

BILLING CODE 4167–05–P

INTERNATIONAL TRADE COMMISSION

[Inv. No. 701–TA–768 (Final)]

Steel Concrete Reinforcing Bar From Algeria; Closure of Investigation

AGENCY: United States International Trade Commission.

ACTION: Notice.

SUMMARY: On March 27, 2026, the Department of Commerce published notice in the **Federal Register** of an affirmative final countervailing duty determination in connection with steel concrete reinforcing bar from Algeria (91 FR 14808). However, the Office of the United States Trade Representative has advised the Commission of its determination that Algeria is not a Subsidies Agreement country (90 FR 34334, July 21, 2025). The Commission did not make a preliminary determination for the countervailing duty investigation concerning steel concrete reinforcing bar from Algeria and does not make a final determination for the countervailing duty investigation concerning steel concrete reinforcing bar from Algeria (See 19 U.S.C. 1671(c)). Accordingly, the Commission's countervailing duty investigation concerning steel concrete reinforcing bar from Algeria (Investigation No. 701–TA–768 (Final)) is closed.

DATES: March 27, 2026.

FOR FURTHER INFORMATION CONTACT: Douglas Corkran ((202) 205–3057) or Sharon Fisher ((202) 205–2431), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office

of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (*https://www.usitc.gov*). The public record for this matter may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.*

Authority: This investigation is being closed under authority of section 701(c)(1) & (5) of the Tariff Act of 1930 (19 U.S.C. 1671(c)(1) & (5)). This notice is published pursuant to section 201.10 of the Commission's rules (19 CFR 201.10).

By order of the Commission.

Issued: May 18, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–10080 Filed 5–19–26; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1717]

Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Organix Chemistry Solutions, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 20, 2026. Such persons may also file a written request for a hearing on the application on or before July 20, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 28, 2026, Organix Chemistry Solutions, LLC, 32 Cabot Road, Woburn, Massachusetts 01801–1004, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methamphetamine	1105	II

The company plans to synthesize the listed controlled substance for distribution to its customers. No other activity for this drug code is authorized for this registration.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–10087 Filed 5–19–26; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1716]

Importer of Controlled Substances Application: Amneal Pharmaceuticals, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Amneal Pharmaceuticals, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before June 22, 2026. Such persons may also file a written request for a hearing on the application on or before June 22, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 4, 2026, Amneal Pharmaceuticals, LLC, 47 Colonial Drive, Piscataway, New Jersey 08854, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Remifentanil	9739	II

The company plans to import the above listed controlled substance as finished unit formulations for internal development and research purposes only. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration- approved or non approved finished dosage forms for commercial sale.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–10089 Filed 5–19–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–372]

Exempt Chemical Preparations Under the Controlled Substances Act

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Order with opportunity for comment.